1. A 34-year-old man with schizophrenia was started on risperidone 4 mg daily three weeks ago. He now presents to clinic reporting that he cannot sit still, feels internally restless, and has been pacing his apartment for hours each day. His treating psychiatrist, interpreting this as worsening psychosis, increases his risperidone dose to 6 mg daily. Over the next week his symptoms worsen substantially. Which of the following best describes both the correct diagnosis and the most appropriate initial pharmacological intervention?
A) Drug-induced parkinsonism (DIP) treated with benztropine 1 to 2 mg orally twice daily to restore dopaminergic-cholinergic balance in the nigrostriatal pathway.
B) Tardive dyskinesia (TD) treated with valbenazine 40 mg once daily, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that depletes presynaptic dopamine.
C) Akathisia treated with propranolol 20 to 80 mg per day, which addresses the subjective restlessness component through beta-adrenergic blockade.
D) Acute dystonia treated with diphenhydramine 50 mg intramuscularly, which rapidly reverses involuntary muscle contractions through muscarinic receptor blockade.
E) Neuroleptic malignant syndrome (NMS) treated with dantrolene and immediate discontinuation of risperidone.
ANSWER: C
Rationale:
Option C is correct. This presentation — inner restlessness, inability to sit still, and pacing — is classic akathisia, the most clinically underrecognized extrapyramidal side effect (EPS). The psychiatrist's error of interpreting akathisia as worsening psychosis and escalating the dose is a well-documented clinical mistake that invariably worsens the syndrome. Propranolol 20 to 80 mg per day is the most effective pharmacological intervention for the subjective restlessness component of akathisia, acting through beta-1 and beta-2 adrenergic blockade. Dose reduction of the antipsychotic is the first and most effective intervention overall, but when pharmacological treatment is added, propranolol has the strongest evidence.
Option A: Option A is incorrect. Drug-induced parkinsonism presents with bradykinesia, rigidity, and tremor — the classic parkinsonian triad — not with subjective restlessness and pacing. Benztropine is appropriate for DIP and acute dystonia, but not for akathisia, where anticholinergics are generally ineffective.
Option B: Option B is incorrect. Tardive dyskinesia is a late-onset hyperkinetic movement disorder (orofacial choreiform movements) emerging after months to years of antipsychotic exposure, not after three weeks. Valbenazine is the correct treatment for TD, not for akathisia.
Option D: Option D is incorrect. Acute dystonia presents with involuntary, sustained muscle contractions — torticollis, oculogyric crisis, opisthotonus — typically within hours to days of starting an antipsychotic. This patient's presentation lacks any fixed posturing or involuntary contractions; diphenhydramine would not address akathisia.
Option E: Option E is incorrect. NMS presents with the tetrad of hyperthermia, lead-pipe rigidity, autonomic instability, and altered mental status — none of which are present here. Akathisia does not involve fever, rigidity, or autonomic dysregulation.
2. A 19-year-old man received haloperidol 5 mg intramuscularly in the emergency department for acute agitation associated with a first psychotic episode. Approximately 90 minutes later, nursing staff find him in severe distress with his neck twisted sharply to the left, his eyes deviated upward and to the right, and his back arched. He is unable to straighten his neck voluntarily and is in significant pain. Which of the following is the most appropriate immediate treatment?
A) Benztropine 2 mg intramuscularly or intravenously, which reverses acute dystonia through muscarinic receptor blockade, restoring dopaminergic-cholinergic balance in the nigrostriatal pathway.
B) Propranolol 40 mg orally, which addresses the adrenergic component of the reaction through beta-1 and beta-2 receptor blockade.
C) Valbenazine 80 mg orally, a selective VMAT2 inhibitor that reduces presynaptic dopamine release and resolves hyperkinetic extrapyramidal reactions.
D) Lorazepam 2 mg intravenously, which is the definitive treatment for acute dystonia through GABA-A receptor potentiation and reduction of motor cortex excitability.
E) Discontinue haloperidol and observe, as acute dystonic reactions are self-limiting and resolve spontaneously within 30 to 60 minutes without pharmacological intervention.
ANSWER: A
Rationale:
Option A is correct. This is a classic acute dystonic reaction — torticollis (involuntary neck rotation), oculogyric crisis (upward and lateral eye deviation), and opisthotonus (back arching) — occurring within hours of a high-potency first-generation antipsychotic (FGA). Acute dystonia results from abrupt D2 blockade in the nigrostriatal pathway, disrupting the normal dopaminergic-cholinergic balance and producing unopposed cholinergic activity driving sustained involuntary muscle contraction. Benztropine 2 mg IM or IV rapidly restores this balance through muscarinic receptor blockade and is the treatment of choice; diphenhydramine 50 mg IM or IV is an equally effective alternative. Onset of relief is typically within 5 to 15 minutes.
Option B: Option B is incorrect. Propranolol addresses the subjective restlessness and adrenergic component of akathisia — a completely different EPS syndrome — and has no role in acute dystonia. Beta-adrenergic blockade does not reverse cholinergic-excess-mediated muscle contractions.
Option C: Option C is incorrect. Valbenazine is a VMAT2 inhibitor approved specifically for tardive dyskinesia (TD), a late-onset hyperkinetic syndrome distinct from acute dystonia. It has no role in acute EPS management and would not produce rapid reversal of a dystonic crisis.
Option D: Option D is incorrect. Benzodiazepines can provide adjunctive sedation and some muscle relaxation in dystonic reactions but are not the definitive treatment. Lorazepam works via GABA-A potentiation, which does not address the underlying dopaminergic-cholinergic imbalance and does not produce the rapid, reliable reversal that anticholinergic agents provide.
Option E: Option E is incorrect. Acute dystonic reactions are not self-limiting within 30 to 60 minutes and cause significant pain and distress. This patient has torticollis, oculogyric crisis, and opisthotonus — a severe reaction requiring immediate pharmacological intervention, not observation.
3. A 47-year-old woman with schizophrenia has developed tardive dyskinesia (TD) after 8 years of antipsychotic therapy, manifesting as repetitive lip-smacking, tongue protrusion, and choreiform finger movements. Her psychiatrist initiates valbenazine for TD. Which of the following most accurately describes valbenazine's mechanism of action, dosing schedule, primary metabolic pathway, and most common dose-dependent adverse effect?
A) Valbenazine blocks postsynaptic dopamine D2 receptors in the striatum, is dosed twice daily, is metabolized primarily by CYP2D6, and most commonly causes akathisia as its principal adverse effect.
B) Valbenazine inhibits dopamine reuptake at the presynaptic terminal, is dosed once daily, is metabolized by CYP2C19, and most commonly causes insomnia as its principal adverse effect.
C) Valbenazine enhances GABAergic inhibition in the indirect pathway of the basal ganglia, is dosed once daily, requires no dose adjustment with CYP inhibitors, and most commonly causes weight gain as its principal adverse effect.
D) Valbenazine depletes presynaptic dopamine by blocking the vesicular monoamine transporter 2 (VMAT2), is dosed twice daily, is metabolized by CYP2D6, and most commonly causes depression as its principal adverse effect.
E) Valbenazine selectively inhibits the vesicular monoamine transporter 2 (VMAT2), reducing presynaptic dopamine loading into synaptic vesicles, is dosed once daily, is metabolized by CYP3A4 to its active monohydrolyzed metabolite, and most commonly causes somnolence as its principal dose-dependent adverse effect.
ANSWER: E
Rationale:
Option E is correct. Valbenazine is a highly selective VMAT2 inhibitor that reduces the loading of dopamine into presynaptic vesicles, thereby decreasing dopamine release at the nigrostriatal synapse and attenuating the postsynaptic D2 receptor supersensitivity thought to underlie TD. Its key clinical pharmacology features are: once-daily dosing (40 mg for week 1, then 80 mg; patients not tolerating 80 mg may continue at 40 mg); metabolism by CYP3A4 to its active monohydrolyzed metabolite (strong CYP3A4 inhibitors increase valbenazine exposure and require dose reduction); and somnolence as the most common dose-dependent adverse effect, which is important to counsel patients about and monitor, particularly in those operating vehicles or machinery.
Option A: Option A is incorrect. Valbenazine does not block D2 receptors — that is the mechanism of antipsychotics and metoclopramide. D2 blockade is the mechanism that causes TD, not the mechanism of its treatment. Valbenazine is also not primarily metabolized by CYP2D6 and is not dosed twice daily.
Option B: Option B is incorrect. Valbenazine does not inhibit dopamine reuptake — that is the mechanism of agents such as methylphenidate and cocaine. Its metabolic pathway is CYP3A4, not CYP2C19, and insomnia is not its characteristic adverse effect; somnolence is.
Option C: Option C is incorrect. Valbenazine does not act through GABAergic mechanisms. Enhancement of GABA in the indirect pathway is the mechanism of benzodiazepines and barbiturates, not VMAT2 inhibitors. Strong CYP3A4 inhibitors do require dose adjustment.
Option D: Option D is incorrect. While the general mechanism description (presynaptic dopamine depletion via VMAT2) is partially correct, valbenazine is dosed once daily — not twice daily — and is metabolized by CYP3A4, not CYP2D6. Depression and suicidality are class warnings for VMAT2 inhibitors but are not the most common dose-dependent adverse effect; somnolence is.
4. A neurology resident is comparing the two FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors for tardive dyskinesia (TD). A colleague asks how deutetrabenazine differs from valbenazine in terms of its origin, dosing schedule, and the pivotal clinical trial supporting its approval. Which of the following responses is most accurate?
A) Deutetrabenazine is a novel compound unrelated to any prior drug, is dosed once daily, and was approved based on the KINECT 3 trial demonstrating reduction in Abnormal Involuntary Movement Scale (AIMS) scores versus placebo.
B) Deutetrabenazine is derived from tetrabenazine through deuterium substitution, which extends its half-life and permits twice-daily dosing, and was approved based on the AIM-TD trial demonstrating significant reduction in AIMS scores versus placebo.
C) Deutetrabenazine is a prodrug of valbenazine that undergoes hepatic conversion to the same active monohydrolyzed metabolite, is dosed once daily, and was studied in the KINECT 3 trial.
D) Deutetrabenazine directly blocks postsynaptic D2 receptors in the striatum and was approved for TD based on a meta-analysis of FGA trials showing reduced movement scores with dopamine antagonism.
E) Deutetrabenazine inhibits dopamine synthesis by blocking tyrosine hydroxylase, is dosed three times daily due to its short half-life, and was approved based on the VANISH-TD trial.
ANSWER: B
Rationale:
Option B is correct. Deutetrabenazine is structurally derived from tetrabenazine, an older VMAT2 inhibitor used for chorea in Huntington's disease, through deuterium substitution at specific carbon-hydrogen bonds. Deuterium substitution slows hepatic oxidative metabolism (because the carbon-deuterium bond is stronger than the carbon-hydrogen bond), extending the half-life of active metabolites and permitting twice-daily dosing compared with the three-times-daily dosing required for tetrabenazine. The pivotal approval trial for deutetrabenazine in TD was the AIM-TD (Addressing Involuntary Movements — Tardive Dyskinesia) trial, a phase 3 randomized, double-blind, placebo-controlled study published in Lancet Psychiatry (2017) that demonstrated significant reduction in AIMS scores across multiple dose arms.
Option A: Option A is incorrect. Deutetrabenazine is not a novel compound — it is directly derived from tetrabenazine. It is dosed twice daily, not once daily (once-daily dosing is the feature of valbenazine). The KINECT 3 trial is the pivotal valbenazine trial, not the deutetrabenazine trial.
Option C: Option C is incorrect. Deutetrabenazine and valbenazine are structurally distinct compounds with different metabolic pathways; deutetrabenazine is not a prodrug of valbenazine and does not share its active metabolite.
Option D: Option D is incorrect. Neither deutetrabenazine nor valbenazine acts through D2 receptor blockade — that mechanism causes TD, not treats it. Both agents work by depleting presynaptic dopamine via VMAT2 inhibition.
Option E: Option E is incorrect. Deutetrabenazine does not inhibit tyrosine hydroxylase — that is the mechanism of metyrosine (alpha-methyltyrosine), used in pheochromocytoma. There is no VANISH-TD trial; the deutetrabenazine pivotal trial is AIM-TD.
5. A 55-year-old woman with treatment-resistant schizophrenia has been maintained on clozapine for 6 years with good psychiatric stability. She now presents with repetitive orofacial movements including lip smacking, tongue protrusion, and grimacing that have been worsening over 8 months. Her psychiatrist confirms a diagnosis of tardive dyskinesia (TD). The team is reluctant to reduce or discontinue clozapine given her history of multiple hospitalizations on other agents. Which of the following best describes the most appropriate management strategy?
A) Discontinue clozapine immediately, as continuing a D2-blocking agent in the presence of TD constitutes a formal contraindication and will inevitably cause irreversible progression.
B) Switch clozapine to aripiprazole, which as a partial D2 agonist has the lowest TD liability of any antipsychotic and will allow the existing TD to resolve spontaneously over weeks.
C) Add tetrabenazine, titrating to three times daily dosing, as it is the FDA-approved first-line agent for antipsychotic-induced TD and requires no monitoring for depression.
D) Add valbenazine or deutetrabenazine, as VMAT2 inhibitors treat TD by depleting presynaptic dopamine without requiring antipsychotic discontinuation, resolving the clinical dilemma of balancing TD management against psychiatric stability.
E) Increase the clozapine dose, as higher clozapine plasma levels suppress TD through enhanced D4 receptor occupancy in the striatum.
ANSWER: D
Rationale:
Option D is correct. The central clinical dilemma in TD occurring during ongoing antipsychotic therapy is that reducing or discontinuing the antipsychotic risks psychiatric decompensation, while continuing it perpetuates the mechanism driving TD. VMAT2 inhibitors — valbenazine and deutetrabenazine — resolve this dilemma precisely because they treat TD by depleting presynaptic dopamine at the level of vesicular storage, without requiring the antipsychotic to be stopped. This patient has good psychiatric stability on clozapine after a difficult treatment history; VMAT2 inhibitor addition allows TD management while preserving that stability. Additionally, clozapine itself has the lowest TD liability of all antipsychotics and may suppress TD in patients switched from other agents — switching away from clozapine would not be the preferred approach here.
Option A: Option A is incorrect. Continuing a dopamine-blocking agent in the presence of TD is not a formal absolute contraindication. The clinical decision involves weighing the psychiatric risk of discontinuation against the movement disorder burden. VMAT2 inhibitors exist precisely to allow treatment without mandatory discontinuation.
Option B: Option B is incorrect. While aripiprazole has low TD liability and partial D2 agonism is associated with lower rates of new TD, switching from clozapine to aripiprazole in a treatment-resistant patient with established stability is high-risk. Existing TD does not reliably resolve spontaneously on switching to a lower-liability agent.
Option C: Option C is incorrect. Tetrabenazine is FDA-approved for chorea in Huntington's disease, not specifically for antipsychotic-induced TD. The FDA-approved VMAT2 inhibitors for TD are valbenazine and deutetrabenazine. Tetrabenazine requires three-times-daily dosing and carries a boxed warning for depression and suicidality, requiring monitoring.
Option E: Option E is incorrect. Increasing the clozapine dose would suppress TD movements transiently through increased D2 occupancy, but this is a masking effect — it worsens the underlying D2 supersensitivity pathophysiology and will lead to TD rebound and progression. D4 receptor occupancy is not the mechanism by which any antipsychotic suppresses TD.
6. A 28-year-old man with schizophrenia was started on haloperidol 10 mg daily 10 days ago. He is brought to the emergency department by his family with fever of 40.2°C, generalized lead-pipe muscle rigidity, blood pressure fluctuating between 90/60 and 160/110 mmHg, heart rate of 128 beats per minute, profuse diaphoresis, and confusion. Creatine kinase (CK) is 18,400 U/L. Which of the following is the single most important immediate action?
A) Discontinue haloperidol and all other dopamine-blocking agents immediately, as removing the offending agent is the essential first step in NMS management without which all other interventions are inadequate.
B) Administer dantrolene 2.5 mg/kg intravenously immediately, as pharmacological reduction of muscle rigidity is the highest priority and must precede all other interventions including drug discontinuation.
C) Administer lorazepam 2 mg intravenously to reduce agitation and sympathetic tone while arranging transfer to the intensive care unit (ICU) for further workup.
D) Obtain an urgent neurology consultation before making any medication changes, as neuroleptic malignant syndrome (NMS) cannot be diagnosed without ruling out primary central nervous system pathology first.
E) Start bromocriptine 2.5 mg orally three times daily to restore dopaminergic tone at the hypothalamic level before discontinuing haloperidol, which could precipitate acute dopaminergic rebound.
ANSWER: A
Rationale:
Option A is correct. In neuroleptic malignant syndrome (NMS), immediate discontinuation of all dopamine-blocking agents — including antipsychotics, metoclopramide, and prochlorperazine if present — is the single most critical first step. NMS is driven by ongoing D2 receptor blockade disrupting hypothalamic thermoregulation and initiating a self-amplifying cycle of muscle rigidity, hyperthermia, and autonomic instability. Without removing the causative agent, the pathophysiological cascade cannot be interrupted and all other interventions operate against a continuing insult. This patient has all four cardinal features of NMS: hyperthermia (40.2°C), lead-pipe rigidity, autonomic instability (labile blood pressure, tachycardia, diaphoresis), and altered mental status — along with markedly elevated CK indicating rhabdomyolysis. Immediate drug discontinuation must occur simultaneously with aggressive cooling, IV fluid resuscitation, and ICU-level monitoring.
Option B: Option B is incorrect. Dantrolene is an important pharmacological intervention in severe NMS (loading dose 1 to 2.5 mg/kg IV), but it does not take priority over drug discontinuation. Dantrolene reduces rigidity and heat production by inhibiting sarcoplasmic reticulum calcium release in skeletal muscle, but it cannot arrest NMS if the causative dopamine blockade continues. Drug discontinuation and dantrolene are both urgent but discontinuation is the essential prerequisite.
Option C: Option C is incorrect. Lorazepam provides useful adjunctive benefit — reducing agitation and sympathetic tone — and ICU transfer is appropriate, but these are not the single most important immediate action. Continuing haloperidol while only providing benzodiazepine sedation would allow NMS to progress.
Option D: Option D is incorrect. NMS is a clinical diagnosis based on the characteristic tetrad in the context of antipsychotic exposure. Waiting for neurology consultation before discontinuing the antipsychotic would delay the most critical intervention and allow continued pathophysiological progression. Primary CNS pathology should be considered in the differential, but this does not preclude immediate drug discontinuation.
Option E: Option E is incorrect. There is no evidence that abrupt antipsychotic discontinuation in NMS causes a dangerous dopaminergic rebound requiring pretreatment with bromocriptine. Bromocriptine is a useful adjunct in NMS — partially restoring dopaminergic tone — but it is initiated after, not before, discontinuing the offending agent.
7. A 35-year-old woman with schizoaffective disorder develops neuroleptic malignant syndrome (NMS) with temperature of 40.8°C, severe generalized rigidity, and creatine kinase (CK) of 42,000 U/L. The offending antipsychotic has been discontinued, aggressive cooling initiated, and IV fluid resuscitation begun. The team decides to add dantrolene. Which of the following best explains the mechanism by which dantrolene reduces muscle rigidity and hyperthermia in NMS?
A) Dantrolene blocks GABA-A receptors in the motor cortex, interrupting upper motor neuron drive and reducing the descending excitatory input responsible for generalized rigidity.
B) Dantrolene is a dopamine agonist at hypothalamic D2 receptors that partially restores dopaminergic tone, reversing the hypothalamic thermoregulatory dysfunction driving hyperthermia.
C) Dantrolene inhibits calcium release from the sarcoplasmic reticulum (SR) of skeletal muscle fibers by blocking the ryanodine receptor, directly reducing myofibrillar contraction and the heat generated by sustained ATP hydrolysis in rigid muscle.
D) Dantrolene enhances norepinephrine reuptake at the neuromuscular junction (NMJ), reducing sympathetic activation of skeletal muscle and attenuating the autonomic instability component of NMS.
E) Dantrolene competitively antagonizes acetylcholine at nicotinic receptors at the NMJ, producing chemical neuromuscular blockade that reduces the rigidity without affecting consciousness or respiratory drive.
ANSWER: C
Rationale:
Option C is correct. Dantrolene is a direct-acting muscle relaxant that acts at the level of the skeletal muscle fiber itself — not at the neuromuscular junction (NMJ), not in the spinal cord, and not in the brain. It inhibits calcium release from the sarcoplasmic reticulum (SR) by blocking the ryanodine receptor (RyR1), which is the calcium release channel activated during excitation-contraction coupling. In NMS, the pathophysiological cycle involves sustained muscle rigidity driven by unchecked motor activity, which generates massive heat through myofibrillar ATP hydrolysis; hyperthermia then impairs the calcium reuptake machinery (SERCA), perpetuating rigidity, which generates more heat. Dantrolene interrupts this cycle at the SR calcium release step, reducing contractile force, decreasing heat production, and breaking the rigidity-hyperthermia feedback loop. The standard NMS dosing is a loading dose of 1 to 2.5 mg/kg IV, then 1 mg/kg every 6 hours up to 10 mg/kg per day.
Option A: Option A is incorrect. Dantrolene does not act at GABA-A receptors or in the motor cortex. GABA-A modulation is the mechanism of benzodiazepines, which provide adjunctive benefit in NMS by reducing agitation and sympathetic tone but do not directly address the muscle rigidity-hyperthermia cycle.
Option B: Option B is incorrect. Dantrolene has no dopamine agonist activity. Partial restoration of hypothalamic dopaminergic tone is the mechanism of bromocriptine and amantadine, which are co-administered in NMS for this purpose but act by a completely different mechanism from dantrolene.
Option D: Option D is incorrect. Dantrolene does not affect norepinephrine reuptake at the NMJ or anywhere else. It acts exclusively at the SR calcium release channel within the muscle fiber.
Option E: Option E is incorrect. Dantrolene is not a nicotinic receptor antagonist and does not produce neuromuscular blockade. Non-depolarizing NMJ blockers (e.g., rocuronium, vecuronium) could theoretically reduce rigidity in refractory NMS requiring intubation, but this is a separate class of agents with a completely different mechanism and safety profile.
8. A 41-year-old woman with bipolar disorder and depression is admitted with fever of 39.4°C, muscle stiffness, diaphoresis, tachycardia, and confusion. She takes olanzapine 10 mg nightly and was started on sertraline 50 mg daily two weeks ago by her primary care physician. On examination she has generalized muscle rigidity that is severe and uniform throughout the range of motion, brisk but symmetric deep tendon reflexes, and no clonus. CK is 8,200 U/L. Which of the following best distinguishes the most likely diagnosis from the primary alternative diagnosis in this case?
A) The presence of fever above 38°C is specific to NMS and does not occur in serotonin syndrome, making hyperthermia the key distinguishing feature between the two syndromes.
B) The elevated CK confirms rhabdomyolysis, which is pathognomonic for serotonin syndrome and excludes NMS, as NMS does not cause significant skeletal muscle injury.
C) The combination of olanzapine and sertraline together is diagnostic of NMS because SGAs always cause NMS when combined with SSRIs, making further workup unnecessary.
D) The two-week latency from sertraline initiation to symptom onset is pathognomonic for NMS, as serotonin syndrome always presents within 24 hours of drug initiation and therefore cannot present at this timepoint.
E) The lead-pipe rigidity — severe, generalized, and uniform throughout the range of motion — is the key distinguishing feature favoring NMS over serotonin syndrome; serotonin syndrome characteristically produces hyperreflexia, clonus, and myoclonus rather than the uniform lead-pipe rigidity of NMS.
ANSWER: E
Rationale:
Option E is correct. The single most clinically useful differentiating feature between NMS and serotonin syndrome is the character of the muscle findings. NMS produces lead-pipe rigidity — severe, generalized, and uniform throughout the passive range of motion — reflecting unchecked motor output from D2 blockade in the basal ganglia and its descending pathways. Serotonin syndrome, in contrast, produces a hyperkinetic neuromuscular picture: hyperreflexia, clonus (particularly lower extremity), myoclonus, and tremor, reflecting excessive serotonergic activity at 5-HT1A and 5-HT2A receptors in the brainstem and spinal cord. In this patient, the generalized lead-pipe rigidity without clonus strongly favors NMS. The presence of olanzapine (a D2 blocker) is the likely causative agent; sertraline at 50 mg for two weeks is unlikely to produce the serotonergic excess required for serotonin syndrome at this dose and duration.
Option A: Option A is incorrect. Fever occurs in both NMS and serotonin syndrome and is not specific to either. Hyperthermia is a shared feature; the character of the motor findings, not the presence of fever, is the key differentiator.
Option B: Option B is incorrect. Rhabdomyolysis with CK elevation occurs in both NMS (from sustained muscle rigidity and ATP hydrolysis) and severe serotonin syndrome (from myoclonus and rigidity). CK elevation is not pathognomonic for either syndrome.
Option C: Option C is incorrect. SGAs do not always cause NMS when combined with SSRIs — NMS is an idiosyncratic reaction occurring in approximately 0.01 to 0.02% of patients on antipsychotics. The combination of olanzapine and sertraline does not by itself diagnose NMS; clinical features must be present.
Option D: Option D is incorrect. While serotonin syndrome typically presents rapidly — often within 24 hours of a drug change — it can present up to several days later, particularly with longer-acting agents or cumulative dose escalation. The two-week latency is more consistent with NMS, but serotonin syndrome cannot be excluded on timing grounds alone. The neurological examination findings are the critical distinguishing element.
9. A 30-year-old man with schizophrenia survived a confirmed episode of neuroleptic malignant syndrome (NMS) attributed to fluphenazine. His NMS fully resolved over 12 days. His psychiatric symptoms are now re-emerging and his treatment team is considering antipsychotic rechallenge. Which of the following best describes the correct approach to rechallenge after NMS?
A) Antipsychotic rechallenge after NMS is absolutely contraindicated for life, regardless of the antipsychotic chosen or the interval since recovery, due to an estimated 80% recurrence risk on any dopamine-blocking agent.
B) Rechallenge should be delayed at least 2 weeks after full NMS resolution, should use the lowest available dose of the agent with the lowest D2 affinity — preferably quetiapine or clozapine — and must involve close monitoring for early signs of NMS recurrence; recurrence risk with a different, lower-potency agent is substantially lower than the approximately 30% overall rechallenge recurrence rate.
C) Rechallenge can begin immediately after fever and rigidity resolve, using the same antipsychotic at a lower dose, as prior NMS does not predict recurrence with the same agent if the dose is reduced by at least 50%.
D) Rechallenge should be delayed 6 months after NMS resolution and should use only clozapine, as clozapine is the only antipsychotic that does not carry any risk of NMS recurrence due to its fast-dissociating D2 binding kinetics.
E) Rechallenge timing is not evidence-based and should be left entirely to patient preference, as NMS recurrence risk is not affected by the choice of antipsychotic agent or the duration of the drug-free interval.
ANSWER: B
Rationale:
Option B is correct. The approach to antipsychotic rechallenge after NMS is governed by three evidence-based principles: timing, agent selection, and monitoring. Rechallenge should be delayed at least 2 weeks after full resolution of all NMS features — fever, rigidity, autonomic instability, and mental status — to allow complete recovery of normal thermoregulatory and dopaminergic function. The agent chosen should have the lowest available D2 receptor affinity; quetiapine and clozapine are the preferred agents because their low and fast-dissociating D2 occupancy produces far less nigrostriatal blockade than high-potency FGAs or risperidone. The overall rechallenge recurrence risk is estimated at approximately 30%, but this risk is substantially reduced when a different, lower-potency agent is used rather than the original offending drug. Close monitoring for early NMS signs — any fever, new rigidity, or autonomic changes — during the rechallenge period is mandatory.
Option A: Option A is incorrect. Rechallenge after NMS is not absolutely contraindicated for life. Many patients with schizophrenia require ongoing antipsychotic therapy, and when psychiatric deterioration becomes clinically significant, rechallenge with careful agent selection and monitoring is an accepted and necessary practice. The recurrence risk is approximately 30% overall, not 80%.
Option C: Option C is incorrect. Rechallenge should not begin immediately after fever and rigidity resolve — full resolution of all features requires approximately 1 to 2 weeks, and at least 2 weeks drug-free after full resolution is the recommended minimum interval. Rechallenging with the same agent, even at a lower dose, carries the highest recurrence risk and is not recommended.
Option D: Option D is incorrect. The recommended minimum interval is 2 weeks after full resolution, not 6 months — though longer intervals are appropriate when the clinical situation permits. While clozapine has the lowest NMS risk by virtue of its D2 kinetics, it is not the only acceptable rechallenge agent, and it does not carry zero NMS risk.
Option E: Option E is incorrect. There is clear evidence that both agent choice and timing affect rechallenge recurrence risk. Using a high-potency FGA immediately after NMS recovery carries a far higher recurrence risk than using quetiapine after an adequate drug-free interval.
10. A 24-year-old man with first-episode schizophrenia is started on olanzapine 10 mg nightly. He weighs 82 kg at baseline. At his 8-week follow-up visit he weighs 87 kg. His fasting glucose and lipid panel from baseline are normal. He has no complaints and reports good symptom control. Which of the following best describes the appropriate clinical response at this visit?
A) No action is required at this visit because a 5 kg weight gain represents a cosmetic concern rather than a medical one, and metabolic intervention is only indicated when the patient develops frank type 2 diabetes mellitus or dyslipidemia.
B) Switch olanzapine to ziprasidone immediately, as any weight gain on an antipsychotic mandates switching to a metabolically neutral agent regardless of the patient's psychiatric response or clinical stability.
C) Order a repeat fasting lipid panel and glucose now, as metabolic monitoring is only indicated at 8 weeks and not again until 12 months, making this the only actionable monitoring step at this timepoint.
D) A weight gain of approximately 6% of baseline body weight at 8 weeks exceeds the 5% threshold that warrants a clinical response — including dietary counseling, exercise referral, and consideration of pharmacological intervention or antipsychotic switch — and repeat fasting glucose and lipids should be obtained at 12 weeks per the standard monitoring schedule.
E) Begin metformin 500 mg twice daily immediately, as pharmacological intervention is mandatory whenever weight gain exceeds 2 kg during the first 8 weeks of antipsychotic therapy.
ANSWER: D
Rationale:
Option D is correct. This patient has gained 5 kg on a baseline of 82 kg, representing a 6.1% increase in body weight, which exceeds the 5% threshold established in consensus monitoring guidelines. Any patient who gains more than 5% of baseline body weight at any monitoring point warrants a clinical response: dietary counseling, exercise referral, and consideration of pharmacological intervention or antipsychotic switch. Weight is assessed at 4, 8, and 12 weeks after antipsychotic initiation; this visit at 8 weeks is therefore a scheduled monitoring point at which the 5% threshold has been crossed. Fasting glucose and lipid panel are repeated at 12 weeks and then annually, so the 8-week visit does not require repeat metabolic labs — but the weight gain finding is clinically actionable now.
Option A: Option A is incorrect. A 5% or greater weight gain threshold is not merely cosmetic — it is a validated clinical signal that warrants structured intervention. Patients with schizophrenia already have elevated baseline rates of cardiovascular disease and diabetes, and antipsychotic-induced weight gain substantially compounds these risks. Waiting for frank diabetes before intervening is not the standard of care.
Option B: Option B is incorrect. Any weight gain does not mandate an immediate antipsychotic switch regardless of psychiatric response. Switching a patient with good first-episode symptom control carries significant psychiatric risk. The threshold for considering a switch is meaningful weight gain that has not responded to counseling or pharmacological adjuncts, not any degree of weight gain.
Option C: Option C is incorrect. Monitoring guidelines call for weight at 4, 8, and 12 weeks and fasting glucose and lipids at 12 weeks and annually — not for repeat metabolic labs at 8 weeks unless specific clinical findings warrant earlier reassessment.
Option E: Option E is incorrect. The threshold for initiating metformin is not 2 kg of weight gain in 8 weeks. Metformin is the recommended first-line pharmacological adjunct when a switch is not feasible and weight gain is established and persistent, but it is not mandated at this early stage before dietary and lifestyle interventions have been implemented.
11. A 38-year-old woman with treatment-resistant schizophrenia has been stable on clozapine for 3 years with no prior hospitalizations. Over this period she has gained 18 kg and now has a fasting glucose of 108 mg/dL and a BMI of 31 kg/m². Her psychiatrist determines that switching from clozapine is not clinically feasible given her treatment history. Which of the following pharmacological adjuncts has the strongest evidence base from randomized controlled trials for reducing antipsychotic-induced weight gain in this clinical context?
A) Metformin 500 to 1000 mg twice daily, which has produced mean weight reductions of 2 to 3 kg and improvements in insulin sensitivity in multiple randomized trials and is the recommended first-line pharmacological adjunct for antipsychotic-induced weight gain when an antipsychotic switch is not feasible.
B) Topiramate 100 to 200 mg daily, which has produced the largest weight reductions of any adjunct studied in antipsychotic-treated patients and is considered the preferred first-line option due to its favorable cognitive profile in schizophrenia.
C) Naltrexone/bupropion combination, which is FDA-approved for chronic weight management and is the standard of care for antipsychotic-induced weight gain based on multiple large phase 3 trials in schizophrenia populations.
D) Liraglutide 3 mg subcutaneously daily, which has the strongest evidence base of any pharmacological adjunct for antipsychotic-induced weight gain and is currently recommended as first-line therapy by major psychiatric guidelines.
E) Aripiprazole augmentation at 15 to 30 mg daily, which produces substantial weight loss through hypothalamic D2 agonism when added to clozapine and is the only adjunct with evidence for both weight reduction and improved metabolic parameters in this context.
ANSWER: A
Rationale:
Option A is correct. Metformin has the strongest and most consistent evidence base from randomized controlled trials for antipsychotic-induced weight gain. Multiple trials in antipsychotic-treated patients — including those on clozapine and olanzapine — have demonstrated mean weight reductions of approximately 2 to 3 kg, reductions in BMI, and improvements in insulin sensitivity and fasting glucose. It is generally well tolerated in this population, does not worsen psychiatric symptoms, and its mechanism — improving insulin sensitivity and reducing hepatic glucose output — is particularly well suited to the insulin resistance component of antipsychotic-induced metabolic syndrome. This patient's fasting glucose of 108 mg/dL (prediabetes range) makes metformin especially appropriate. It is the recommended first-line pharmacological adjunct when switching the antipsychotic is not feasible.
Option B: Option B is incorrect. While topiramate has demonstrated efficacy for weight reduction in some antipsychotic trials, it carries significant cognitive adverse effects — word-finding difficulties, concentration impairment, slowed processing speed — that are particularly burdensome in patients with schizophrenia who already have cognitive deficits. It is not considered a preferred first-line adjunct for antipsychotic-induced weight gain and is not described as having a favorable cognitive profile in this population.
Option C: Option C is incorrect. Naltrexone/bupropion (Contrave) is FDA-approved for chronic weight management in the general population, but it does not have an established evidence base from large trials specifically in antipsychotic-induced weight gain and is not the current standard of care in this context.
Option D: Option D is incorrect. Liraglutide has emerging but limited evidence in antipsychotic-treated populations and is not currently recommended as first-line therapy by major psychiatric guidelines for antipsychotic-induced weight gain.
Option E: Option E is incorrect. Aripiprazole augmentation of clozapine or olanzapine does produce modest weight attenuation through hypothalamic dopaminergic mechanisms and is used clinically, but the magnitude of benefit is modest and variable. It does not have the breadth of randomized trial evidence supporting metformin and is not the recommended first-line adjunct.
12. A 52-year-old woman with bipolar disorder with psychotic features is being treated with ziprasidone 80 mg twice daily. A baseline ECG before initiation showed a QTc of 438 ms. A repeat ECG obtained after 4 weeks of therapy shows a QTc of 468 ms. She has no symptoms of palpitations, presyncope, or syncope. Electrolytes are normal. Which of the following best describes the clinical significance of this finding and the appropriate management threshold?
A) A QTc of 468 ms requires immediate discontinuation of ziprasidone and permanent avoidance of all antipsychotics with any QTc-prolonging potential, as any QTc above 450 ms in a woman indicates impending torsades de pointes (TdP).
B) No action is required because ziprasidone is expected to prolong the QTc by up to 20 ms and this finding represents a pharmacodynamically acceptable and clinically insignificant effect that requires no monitoring adjustment.
C) The QTc of 468 ms represents a 30 ms increase from baseline and does not reach either action threshold — QTc exceeding 500 ms or an increase from baseline exceeding 60 ms — both of which substantially increase TdP risk; continued monitoring is appropriate, with particular attention to electrolytes and co-medications.
D) The QTc increase from 438 to 468 ms is pathognomonic for acquired long QT syndrome and mandates immediate cardiology referral, cardiac catheterization, and permanent antipsychotic discontinuation.
E) Any QTc prolongation on ziprasidone mandates switching to haloperidol intravenously (IV), which carries no QTc risk and is the preferred alternative for patients who develop QTc prolongation on oral antipsychotics.
ANSWER: C
Rationale:
Option C is correct. The two established clinical thresholds for action in antipsychotic-related QTc prolongation are: an absolute QTc exceeding 500 ms, or an increase from baseline exceeding 60 ms. Both thresholds are associated with a substantially increased risk of torsades de pointes (TdP), a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. This patient's QTc of 468 ms does not exceed 500 ms, and the increase from baseline (468 minus 438 = 30 ms) does not exceed 60 ms. The finding is consistent with the expected pharmacodynamic effect of ziprasidone, which produces a mean QTc prolongation of approximately 10 ms at therapeutic doses. Appropriate management is continued monitoring — repeat ECG with electrolyte checks at any dose change, addition of QTc-active co-medications, or onset of symptoms — along with maintaining normal potassium and magnesium levels, which lower the threshold for TdP.
Option A: Option A is incorrect. A QTc of 468 ms does not require immediate discontinuation. The 450 ms threshold for women reflects a higher normal baseline, but 450 ms alone is not an action threshold for discontinuing antipsychotics. The clinically validated thresholds are 500 ms absolute or 60 ms increase from baseline.
Option B: Option B is incorrect. While the magnitude of QTc change here is pharmacologically expected and not yet at an action threshold, calling it clinically insignificant requiring no monitoring adjustment is too dismissive. Ongoing monitoring of QTc, electrolytes, and co-medications is appropriate and represents standard of care.
Option D: Option D is incorrect. A 30 ms increase in QTc during ziprasidone therapy is not pathognomonic for acquired long QT syndrome and does not mandate cardiac catheterization. Acquired long QT syndrome is a clinical diagnosis based on QTc prolongation pattern and excluding other causes, not on any specific numeric change.
Option E: Option E is incorrect. Haloperidol IV at high doses carries substantial QTc risk — among the highest of any antipsychotic formulation — and is specifically listed as a high-risk agent for TdP. It is not an appropriate switch for patients with QTc concerns.
13. A 44-year-old man with treatment-resistant schizophrenia on clozapine 400 mg daily develops a generalized tonic-clonic seizure. His absolute neutrophil count (ANC) has been stable at 2,800 cells per microliter on recent REMS monitoring. The neurology team recommends adding an antiepileptic drug (AED). Which of the following antiepileptic agents is contraindicated in combination with clozapine and why?
A) Valproate, because it significantly increases clozapine plasma levels through CYP1A2 inhibition, leading to dose-dependent neurotoxicity and a greater than 10-fold increase in seizure risk.
B) Lamotrigine, because its glucuronidation pathway is inhibited by clozapine's active metabolite norclozapine, producing lamotrigine toxicity including Stevens-Johnson syndrome in nearly all co-treated patients.
C) Levetiracetam, because its renal elimination pathway competes with clozapine's renal metabolite excretion, causing clozapine accumulation and agranulocytosis in patients with any degree of renal impairment.
D) Phenytoin, because it is a strong CYP1A2 inducer that reduces clozapine plasma levels by more than 90% and simultaneously lowers the seizure threshold through a direct proconvulsant mechanism at therapeutic plasma levels.
E) Carbamazepine, because it is a strong CYP enzyme inducer that substantially reduces clozapine plasma levels and, critically, carries additive bone marrow suppression risk when combined with clozapine, creating a compounded risk of agranulocytosis that makes this combination contraindicated.
ANSWER: E
Rationale:
Option E is correct. Carbamazepine is contraindicated with clozapine for two compounding reasons. First, carbamazepine is a potent inducer of CYP3A4 and other CYP enzymes, which substantially increases clozapine metabolism and reduces clozapine plasma levels — potentially to subtherapeutic concentrations, risking loss of antipsychotic efficacy. Second, and more critically, both clozapine and carbamazepine carry independent risk of bone marrow suppression and agranulocytosis. The combination produces an additive hematological risk that is considered clinically unacceptable. This dual mechanism — pharmacokinetic (CYP induction reducing clozapine levels) and pharmacodynamic (additive myelosuppression) — makes the combination contraindicated. For clozapine-associated seizures, valproate is the preferred AED because it does not affect clozapine plasma levels significantly, does not cause bone marrow suppression, and provides additional mood stabilization in patients with schizoaffective disorder. Lamotrigine is a reasonable alternative that is metabolically neutral and non-myelosuppressive.
Option A: Option A is incorrect. Valproate does not significantly inhibit CYP1A2 (the primary CYP pathway for clozapine metabolism). Valproate is actually the preferred AED in this scenario — not because it is without pharmacokinetic interaction, but because the interaction is manageable and it does not carry additive myelosuppression risk.
Option B: Option B is incorrect. While clozapine's metabolite norclozapine does inhibit UGT1A4 (a glucuronidation enzyme involved in lamotrigine metabolism) to some degree, this interaction requires monitoring of lamotrigine levels but does not produce Stevens-Johnson syndrome in nearly all co-treated patients. Lamotrigine is used clinically with clozapine with dose adjustment and monitoring.
Option C: Option C is incorrect. Levetiracetam is eliminated renally as unchanged drug and does not interact pharmacokinetically with clozapine in any clinically meaningful way. It is considered a safe combination.
Option D: Option D is incorrect. Phenytoin is a CYP inducer but acts primarily on CYP2C9 and CYP2C19; its effect on CYP1A2 (the main clozapine pathway) is less pronounced. More importantly, phenytoin does not carry additive bone marrow suppression risk, which is the specific and critical contraindication that applies to carbamazepine.
14. A psychiatry intern is preparing to initiate clozapine in a 32-year-old man with treatment-resistant schizophrenia who has failed two adequate trials of other antipsychotics. The intern asks the attending about the mandatory absolute neutrophil count (ANC) monitoring schedule required by the Risk Evaluation and Mitigation Strategy (REMS) program before each dispensing of clozapine. Which of the following correctly describes the REMS-mandated ANC monitoring frequency over the first year of clozapine therapy?
A) ANC must be checked daily for the first month, weekly for months 2 through 6, and monthly from month 7 onward, with the patient registered in the national clozapine registry before the first dispensing.
B) ANC must be checked weekly for the first 6 months, biweekly (every 2 weeks) for months 6 through 12, and monthly thereafter, with each dispensing contingent on an ANC result meeting the threshold required for that monitoring phase.
C) ANC must be checked monthly throughout the entire duration of clozapine therapy, with no increased frequency required during the first 6 months, because the peak agranulocytosis risk is evenly distributed across the treatment period.
D) ANC must be checked weekly for the first 18 months and then biweekly indefinitely; monthly monitoring is never permitted because the risk of agranulocytosis does not diminish sufficiently to justify reduced surveillance frequency.
E) ANC monitoring is required only during the first 3 months of therapy, after which dispensing is permitted without ANC results because agranulocytosis risk is negligible beyond the initial risk window.
ANSWER: B
Rationale:
Option B is correct. The clozapine REMS program mandates a specific three-phase ANC monitoring schedule before each dispensing: weekly monitoring for the first 6 months (the highest-risk period, when peak agranulocytosis incidence occurs at approximately 3 to 6 months); biweekly monitoring from months 6 through 12 (reflecting the reduced but still elevated risk in the second 6 months); and monthly monitoring from month 12 onward (reflecting the lower but non-zero ongoing risk). Each dispensing is contingent on an ANC result that meets the threshold for that monitoring phase — pharmacies are required to verify REMS compliance before dispensing. Patient registration in the national clozapine registry (previously four separate manufacturer registries, now consolidated into a single unified REMS program) is mandatory before the first prescription is written.
Option A: Option A is incorrect. Daily ANC monitoring is not required at any phase. The first-phase requirement is weekly monitoring, not daily.
Option C: Option C is incorrect. Monthly monitoring from initiation is not the standard and would miss the peak risk period. The first 6 months carry the highest agranulocytosis risk and require weekly monitoring. Risk is not evenly distributed across the treatment period — it is highest in the first several months.
Option D: Option D is incorrect. The weekly monitoring phase ends after 6 months, not after 18 months. Monthly monitoring is permitted and is the standard after 12 months of stable therapy, because risk does decrease meaningfully over time.
Option E: Option E is incorrect. ANC monitoring is required indefinitely throughout clozapine therapy, not only for the first 3 months. The risk of agranulocytosis does not disappear after 3 months — cases have been reported years into therapy — and lifelong REMS monitoring is mandatory for all clozapine patients.
15. A 46-year-old man with treatment-resistant schizophrenia has been on clozapine 350 mg daily for 14 months with good psychiatric response. He reports severe nocturnal drooling that is affecting his sleep and causing significant distress. His psychiatrist wants to treat the sialorrhea (excessive salivation) with a peripheral anticholinergic agent. Which of the following best explains why glycopyrrolate is preferred over systemic anticholinergics such as benztropine for managing clozapine-induced sialorrhea?
A) Glycopyrrolate is preferred because it has higher affinity for the M4 muscarinic receptor subtype in the submandibular glands than benztropine, directly reversing the agonist mechanism driving clozapine-induced sialorrhea.
B) Glycopyrrolate is preferred because it is a prodrug that is converted to an active metabolite in saliva glands, producing local antisecretory effects without any systemic absorption or anticholinergic adverse effects elsewhere.
C) Glycopyrrolate is preferred because it inhibits alpha-2 adrenergic receptors in salivary gland acinar cells, reducing sympathetic stimulation of salivation through a non-muscarinic mechanism that avoids central side effects entirely.
D) Glycopyrrolate is preferred because it is a quaternary ammonium compound that does not cross the blood-brain barrier (BBB), providing peripheral antisalivary effect through muscarinic blockade in salivary glands without the central anticholinergic effects — cognitive impairment, sedation, confusion — that tertiary amines such as benztropine produce by penetrating the CNS.
E) Glycopyrrolate is preferred because it selectively blocks M3 muscarinic receptors only in salivary glands while sparing all other muscarinic receptor subtypes, making it uniquely tissue-selective with no effect on cardiac or gastrointestinal muscarinic tone.
ANSWER: D
Rationale:
Option D is correct. The key pharmacological property that makes glycopyrrolate the preferred anticholinergic for clozapine-induced sialorrhea is its chemical structure as a quaternary ammonium compound. Quaternary ammonium compounds carry a permanent positive charge that prevents them from crossing lipid bilayers and traversing the blood-brain barrier (BBB). This means glycopyrrolate produces muscarinic receptor blockade in peripheral tissues — including salivary glands, where it reduces salivary secretion effectively — without entering the central nervous system. In contrast, tertiary amine anticholinergics such as benztropine, trihexyphenidyl, and scopolamine are uncharged at physiological pH and readily cross the BBB, producing central anticholinergic effects including cognitive impairment, confusion, sedation, and worsening of psychotic symptoms at higher doses. In patients with schizophrenia on clozapine — who are already at risk for cognitive impairment — adding central anticholinergic burden is particularly undesirable. Glycopyrrolate avoids this by its peripheral confinement.
Option A: Option A is incorrect. Glycopyrrolate is not preferred because of M4 receptor selectivity. Clozapine's sialorrhea mechanism involves M4 agonism in submandibular glands (a paradoxical effect despite clozapine's general muscarinic antagonism), but glycopyrrolate does not selectively reverse M4 agonism — it is a general muscarinic antagonist. Its advantage is CNS impermeability, not receptor subtype selectivity.
Option B: Option B is incorrect. Glycopyrrolate is not a prodrug converted locally in salivary tissue. It is an active quaternary ammonium anticholinergic administered as such, with its peripheral action resulting from BBB impermeability rather than local activation.
Option C: Option C is incorrect. Glycopyrrolate does not inhibit alpha-2 adrenergic receptors. It is a muscarinic antagonist. Alpha-2 agonism (via low-dose clonidine) is an entirely separate approach to reducing salivation via a different mechanism.
Option E: Option E is incorrect. Glycopyrrolate does not selectively block M3 receptors only in salivary glands while sparing all other subtypes. It is a non-selective muscarinic antagonist with the peripheral restriction arising from its inability to cross the BBB, not from any tissue or receptor subtype selectivity.
16. A 27-year-old man with treatment-resistant schizophrenia was started on clozapine 5 weeks ago, currently at a dose of 200 mg daily following a slow titration. He presents to the emergency department with fever of 38.6°C, chest pain, dyspnea on exertion, and resting tachycardia of 114 beats per minute. Troponin I is elevated at 1.8 ng/mL (reference <0.04 ng/mL). C-reactive protein (CRP) is 68 mg/L. ECG shows sinus tachycardia without ST changes. Which of the following best describes the most appropriate management and the key features of this presentation?
A) This presentation is consistent with clozapine-induced myocarditis — an IgE-mediated hypersensitivity reaction occurring predominantly in the first 6 to 8 weeks of clozapine therapy — and clozapine must be discontinued immediately with urgent cardiology consultation; rechallenge is generally contraindicated.
B) This presentation represents an expected pharmacodynamic effect of clozapine's alpha-1 adrenergic blockade causing reflex tachycardia and should be managed with dose reduction to 100 mg daily and addition of a beta-blocker; cardiac biomarker elevation is incidental.
C) This presentation is consistent with clozapine-induced agranulocytosis causing secondary septic myocarditis; the priority is checking the ANC and initiating broad-spectrum antibiotics before making any changes to clozapine.
D) This presentation likely represents benign clozapine-associated pericarditis that self-resolves within 2 to 4 weeks without requiring drug discontinuation; NSAIDs and monitoring are the appropriate management.
E) This presentation reflects clozapine's dose-dependent QTc prolongation causing tachyarrhythmia; a 12-lead ECG should be repeated and clozapine continued until QTc exceeds 500 ms, at which point dose reduction is appropriate.
ANSWER: A
Rationale:
Option A is correct. This presentation — fever, chest pain, dyspnea, tachycardia, markedly elevated troponin, and elevated CRP at 5 weeks into clozapine titration — is the classic clinical picture of clozapine-induced myocarditis. The temporal pattern is defining: clozapine myocarditis occurs predominantly within the first 6 to 8 weeks of therapy, with peak incidence around weeks 2 through 4. The mechanism is thought to involve an IgE-mediated hypersensitivity reaction to clozapine metabolites producing myocardial inflammation, explaining the fever and elevated inflammatory markers alongside cardiac biomarker elevation. The response is immediate discontinuation of clozapine, urgent cardiology consultation, and close hemodynamic monitoring. Rechallenge with clozapine after confirmed myocarditis is generally contraindicated given the risk of recurrence. Baseline troponin and CRP before initiating clozapine with weekly monitoring for the first 4 weeks — and at any cardiac symptoms — is recommended, particularly given the severity of this complication when missed.
Option B: Option B is incorrect. Clozapine's alpha-1 blockade does cause orthostatic hypotension and reflex tachycardia during initiation, but a troponin of 45 times the upper limit of normal and a markedly elevated CRP cannot be attributed to hemodynamic reflex mechanisms. This is not an expected pharmacodynamic effect. Dose reduction and beta-blockade would leave an active myocarditis untreated.
Option C: Option C is incorrect. The ANC in this patient has been stable per the description, and the clinical picture is not that of septic myocarditis — there is no described source of infection, no leukocytosis suggesting agranulocytosis-related infection, and the timing is classic for clozapine myocarditis. Delaying clozapine discontinuation while pursuing sepsis workup would be dangerous.
Option D: Option D is incorrect. Clozapine-associated myocarditis is not a benign self-resolving condition manageable with NSAIDs. It can progress to cardiomyopathy or fulminant cardiac failure and has caused death in reported cases. Classifying this as pericarditis without investigation and continuing clozapine would be a serious clinical error.
Option E: Option E is incorrect. The presentation does not represent QTc-related tachyarrhythmia. The ECG shows sinus tachycardia without QTc abnormality. Troponin elevation is not caused by QTc prolongation and cannot be normalized by dose reduction. The clinical syndrome — fever, troponin rise, CRP elevation, tachycardia at week 5 — is myocarditis, not a QTc-mediated arrhythmia.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.